A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Last updated: January 6, 2026
Sponsor: Novo Nordisk A/S
Overall Status: Completed

Phase

1

Condition

Obesity

Diabetes Prevention

Hypertriglyceridemia

Treatment

Cagrilintide and Semaglutide

No treatment given

Placebo

Clinical Study ID

NCT06267092
NN9838-4944
  • Ages 18-65
  • All Genders

Study Summary

Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. The study will last for about 6 months.

Part B: The study will look at how CagriSema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. The study will also look at how participants brain works when participants take the medicine. Participants will either get CagriSema or ''dummy'' medicine.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female

  • Aged 18-65 years (both inclusive) at the time of signing informed consent

  • Right-handed as evaluated by the Edinburgh Handedness Inventory

  • Body weight less than or equal to 180 kilogram at screening

For Part A:

  • A score of 7 or less on the 16-item Disinhibition subscale of the Three FactorEating Questionnaire

  • Body mass index between 18.5 and 24.9 kilogram per meter square (both inclusive) atscreening

For Part B:

  • A score of 8 or more on the 16-item Disinhibition subscale of the Three FactorEating Questionnaire

  • Body mass index equal to or above 27.0 kilogram per meter square. Overweight shouldbe due to excess adipose tissue, as judged by the investigator

Exclusion

Exclusion Criteria:

  • Contraindication for magnetic resonance scanning

For Part B:

  • Glycated haemoglobin greater than or equal to 6.5 % (48 millimoles per mole) atscreening

  • History of type 1 or type 2 diabetes mellitus

Study Design

Total Participants: 164
Treatment Group(s): 3
Primary Treatment: Cagrilintide and Semaglutide
Phase: 1
Study Start date:
February 15, 2024
Estimated Completion Date:
December 08, 2025

Connect with a study center

  • Charité Research Organisation GmbH

    Berlin, 10117
    Germany

    Site Not Available

  • Charité - Campus Charité Mitte - Charité Research Organisation GmbH

    Berlin 2950159, 10117
    Germany

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.